OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion
OSR Holdings (NASDAQ: OSRH) appointed Dr. Andreas Niethammer as CEO of Vaximm AG, effective December 1, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OSR Holdings (NASDAQ: OSRH) appointed Dr. Andreas Niethammer as CEO of Vaximm AG, effective December 1, 2025. Dr. Niethammer is Vaximm's scientific co-founder and will lead the company’s oral T‑cell immunotherapy programs, including lead candidate VXM01, which advanced into first‑in‑human studies for pancreatic cancer and glioblastoma and established proof‑of‑concept for oral vector‑based targeting of tumor vasculature.
Under his leadership Vaximm will pursue a forthcoming strategic collaboration to combine its anti‑angiogenic immune activation platform with viral oncolysis technologies that have shown PoC in a completed U.S. FDA Phase 2a study, targeting renal cell carcinoma and other advanced solid tumors.
Positive
- CEO appointment effective December 1, 2025
- VXM01 advanced to first‑in‑human studies with PoC in pancreatic cancer and glioblastoma
- Planned strategic collaboration with oncolytic technology with completed U.S. FDA Phase 2a PoC
Negative
- None.
Details
News Market Reaction – OSRH
On Nov 14, the day this news came out, OSRH closed 8.83% below the previous close.
Data tracked by StockTitan Argus for the Nov 14 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Niethammer, an internationally recognized oncology expert, co-founded Vaximm to translate his pioneering work at The Scripps Research Institute, where he first described the concept of oral T-cell vaccination in a landmark Nature publication (2002). Under his leadership, Vaximm advanced its lead therapeutic vaccine, VXM01, which targets VEGFR-2, into first-in-human clinical studies for pancreatic cancer and glioblastoma, establishing proof-of-concept for oral vector-based immunotherapy targeting tumor vasculature.
Advancing Combination Immuno-Oncology
Under Dr. Niethammer's leadership, Vaximm will focus on integrating its anti-angiogenic immune activation platform with complementary viral oncolysis technologies that have already achieved clinical proof-of-concept (PoC) in a completed
"I am delighted to step into the role of CEO as we enter an exciting new phase where Vaximm's oral vaccination platform can be combined with potent oncolytic and immune-modulating approaches," said Dr. Niethammer. "Our goal is to deliver more durable systemic antitumor responses while maintaining an excellent safety and tolerability profile."
"As the inventor of Vaximm's core platform, Dr. Niethammer uniquely combines scientific vision with deep clinical development experience," said Peter Hwang, CEO of OSR Holdings. "His appointment as Vaximm CEO marks a natural progression as we prepare for the next chapter of scientific innovation and strategic partnerships to accelerate the development of transformative therapies."
About Vaximm AG
Vaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell vaccination platform harnesses live, attenuated bacterial vectors to deliver tumor-associated antigens, inducing robust cellular immune responses. Lead candidate VXM01, targeting VEGFR-2, has demonstrated clinical activity and safety in multiple cancer indications.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve global health outcomes. Learn more at www.OSR-Holdings.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Media & Investor Contacts
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-appoints-scientific-co-founder-dr-andreas-niethammer-as-chief-executive-officer-of-vaximm-ag-to-lead-next-phase-of-immuno-oncology-expansion-302615840.html
SOURCE OSR Holdings
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.